Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Genetic determinants of on-aspirin platelet reactivity: focus on the influence of PEAR1.

W├╝rtz M, Nissen PH, Grove EL, Kristensen SD, Hvas AM.

PLoS One. 2014 Oct 31;9(10):e111816. doi: 10.1371/journal.pone.0111816.

2.

Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics?

Roden DM.

Can J Cardiol. 2013 Jan;29(1):58-66. doi: 10.1016/j.cjca.2012.07.845. Review.

3.

Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes.

Martis S, Peter I, Hulot JS, Kornreich R, Desnick RJ, Scott SA.

Pharmacogenomics J. 2013 Aug;13(4):369-77. doi: 10.1038/tpj.2012.10.

4.

Predicting clopidogrel response using DNA samples linked to an electronic health record.

Delaney JT, Ramirez AH, Bowton E, Pulley JM, Basford MA, Schildcrout JS, Shi Y, Zink R, Oetjens M, Xu H, Cleator JH, Jahangir E, Ritchie MD, Masys DR, Roden DM, Crawford DC, Denny JC.

Clin Pharmacol Ther. 2012 Feb;91(2):257-63. doi: 10.1038/clpt.2011.221.

5.

Protein kinase C regulation of 12-lipoxygenase-mediated human platelet activation.

Yeung J, Apopa PL, Vesci J, Kenyon V, Rai G, Jadhav A, Simeonov A, Holman TR, Maloney DJ, Boutaud O, Holinstat M.

Mol Pharmacol. 2012 Mar;81(3):420-30. doi: 10.1124/mol.111.075630.

6.

PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19.

Scott SA, Sangkuhl K, Shuldiner AR, Hulot JS, Thorn CF, Altman RB, Klein TE.

Pharmacogenet Genomics. 2012 Feb;22(2):159-65. doi: 10.1097/FPC.0b013e32834d4962. No abstract available.

7.

TRITON and beyond: new insights into the profile of prasugrel.

Jakubowski JA, Riesmeyer JS, Close SL, Leishman AG, Erlinge D.

Cardiovasc Ther. 2012 Aug;30(4):e174-82. doi: 10.1111/j.1755-5922.2011.00263.x. Review.

8.

Genetic determinants of platelet response to clopidogrel.

Kubica A, Kozinski M, Grzesk G, Fabiszak T, Navarese EP, Goch A.

J Thromb Thrombolysis. 2011 Nov;32(4):459-66. doi: 10.1007/s11239-011-0611-8. Review.

9.

Clinical, pharmacokinetic, and pharmacogenetic determinants of clopidogrel resistance in Korean patients with acute coronary syndrome.

Park KJ, Chung HS, Kim SR, Kim HJ, Han JY, Lee SY.

Korean J Lab Med. 2011 Apr;31(2):91-4. doi: 10.3343/kjlm.2011.31.2.91.

10.

The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy.

Gurbel PA, Shuldiner AR, Bliden KP, Ryan K, Pakyz RE, Tantry US.

Am Heart J. 2011 Mar;161(3):598-604. doi: 10.1016/j.ahj.2010.12.011.

11.

Clopidogrel: a pharmacogenomic perspective on its use in coronary artery disease.

Terpening C.

Clin Med Insights Cardiol. 2010 Dec 1;4:117-28. doi: 10.4137/CMC.S4323.

12.

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS.

JAMA. 2010 Oct 27;304(16):1821-30. doi: 10.1001/jama.2010.1543.

13.

Platelet aggregation pathway.

Sangkuhl K, Shuldiner AR, Klein TE, Altman RB.

Pharmacogenet Genomics. 2011 Aug;21(8):516-21. doi: 10.1097/FPC.0b013e3283406323. No abstract available.

14.

Responding to the clopidogrel warning by the US food and drug administration: real life is complicated.

Roden DM, Shuldiner AR.

Circulation. 2010 Aug 3;122(5):445-8. doi: 10.1161/CIRCULATIONAHA.110.973362. No abstract available.

Items per page

Supplemental Content

Support Center